Comparative Pharmacology
Head-to-head clinical analysis: AMINOSYN II 10 IN PLASTIC CONTAINER versus HEPATASOL 8.
Peer-Reviewed Evidence
Head-to-head clinical analysis: AMINOSYN II 10 IN PLASTIC CONTAINER versus HEPATASOL 8.
AMINOSYN II 10% IN PLASTIC CONTAINER vs HEPATASOL 8%
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Aminosyn II 10% is a crystalline amino acid solution that provides essential and nonessential amino acids for protein synthesis, maintenance of nitrogen balance, and tissue repair in parenteral nutrition.
HEPATASOL 8% (amino acid injection) provides essential and non-essential amino acids to support protein synthesis and correct nitrogen balance in hepatic encephalopathy. It reduces plasma ammonia levels by promoting urea cycle activity and decreasing aromatic amino acids.
Intravenous infusion: 7-12 g amino acids per kg body weight per day (0.7-1.2 g/kg/day) for adults with normal renal function; typically administered as a 10% solution at a rate not exceeding 0.5 g amino acids/kg/hour.
Intravenous infusion of 500 mL (40 g amino acids) over 3-4 hours, administered once daily or as directed by clinical response.
None Documented
None Documented
Variable depending on individual amino acids; typical of infused amino acids: 0.5-2 hours for most, with clinical context of continuous infusion achieving steady-state within 24 hours.
Approximately 30-60 minutes for individual amino acids; clinical context: rapid clearance supports continuous infusion to maintain plasma levels.
Amino acids are metabolized; excess nitrogen is excreted renally as urea (70-90%) and to a lesser extent in feces (5-10%).
Renal: >95% of administered amino acids are reabsorbed and metabolized; negligible unchanged excretion. Biliary/fecal: <5%
Category C
Category C
Amino Acid Solution
Amino Acid Solution